NICTAVI, means blink in Latin. We are a Blue Ocean, value-driven ophthalmological medical device Startup. Our mission is to create, innovate, and reimagine eye care products and therapies.

Our first product, the patented, novel, Tarsus Eyelid Patch, is a comfortable, effective method of eye closure. Eye closure has been proven to retain moisture, reduce the occurrence and heal epithelial or corneal surface defects, and enhance the effectiveness of eye medicines. This reducing doctor visits, surgeries, pain, irritation, and the chance of infections, preserving people's sight and improving their quality of life.

Soon to be the patient's and doctor's choice for a more comfortable, manageable, therapeutic eye closure treatment option. 

The Tarsus Eyelid Patch is a more patient compliant method of therapeutic eye closure that will transform cornea care. With a leap of value it will replace antiquated, uncomfortable, eye closure devices and techniques for addressing applicable eye health issues. Using design, simple mechanics, and the most advanced materials and adhesives, the Tarsus Eyelid Patch represents a significant improvement in effectiveness and patient comfort in eye closure.

The Tarsus Patch is a device that allows for adding medicine or artificial tears periodically while being worn, or during surgery. The closure stiffness is such that eye drops can be administered to the eye by simply pulling the lower lid down with a finger and applying the drops to the eye without disturbing the position of the patch on the upper tarsus or eyelid. Upon the release of the lower eyelid, the eye is closed again as the upper eyelid is held in the closed position by the applied Tarsus Patch. This reduces or eliminates corneal damage due to a lack of tear production, exposure keratopathy, or drying of the cornea.

There are currently NO COMFORTABLE, effective products designed for the corneal care, eye closure / occlusion, and ocular therapeutics markets. There is a need for a comfortable eye closure device and method to treat Nocturnal Lagophthalmos. Our product can be worn during sleep to address Noctural Lagophthalmos (the cause) and prevent corneal defects or damage, (the symptoms). Nocturnal Lagophthalmos is the inability to close the eyelids during sleep. It may reduce the quality of sleep, cause exposure-related symptoms or, if severe, cause corneal damage (exposure keratopathy). The degree of Lagophthalmos can be minor (obscure Lagophthalmos), or quite obvious. Lagophthalmos - Wikipedia › wiki › Lagophthalmos

In our early stages, we are implementing a Lean Startup Business Model Design starting with Ophthalmologists. The doctors and their patients will be the early adopters and early influencers creating initial awareness and demand for our product.

 We have a business plan that will be implemented after we acquire evidence, and validation from markets and we are ready to scale to the next level. Then the Tarsus Patch will be sold Over The Counter. We will inform markets of our product and method through select nationwide promotion and advertising first via an explainer animation. The resulting public awareness will build our market and brand awareness. We will be educating the public to the healing practice, and the eye health benefits of eye closure, for those with applicable issues and their caregivers and inform them there is now a product and method for their need. 

To heal severe conditions doctors have long been performing a surgical procedure called a Tarsorrhaphy, in which the eyelids are partially sewn together. Our Tarsus Patch is a less extreme and painless method of eye closure that allows the patient or caregiver to maintain the closure therapy as needed or prescribed.

Our Tarsus Eyelid Patch was created from the patient / customer's perspective, and it is the guiding principle of our entire business model.

(See: Building Business Models on Customer Insights in the Business Model Generation by Alexander Osterealder & Yves Pigner.)

Nictavi is a registered Trademark. SN #88446381. We are a Limited Liability Company.